ARCHIVES

FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | March 16, 2007

Download PDF Visit The Full Archive

Related Articles

NCCS Begins Program To Help Develop Survivors’ Care Plan

February 27, 2009

BMS, Exelixis To Collaborate On Drug Development.

July 27, 2001

New Carfilzomib Combination Produces Near Remissions

June 29, 2012

Kyprolis Demonstrates Overall Response Following FDA Accelerated Approval

August 31, 2012

In Brief: Susan O’Brien to move to UC Irvine Health

November 14, 2014

Cancer Genetics: risk from Three BRCA Mutations Lower Than Expected, NCI Finds

May 23, 1997